Group 5A: HER2+/ER+ Breast Cancer; Novel Targets & Treatments; Predictive Biomarkers

Poster #P2-03-17: Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+ or HER2- metastatic breast cancer

Poster #P3-07-16: Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models

Sold out!

Waiting List

You're the first user in the Waiting List.


Dec 15 2022


2:00 pm - 3:30 pm

Zoom Webinar